ArticleAnnals of gastroenterology
Isolated immune-mediated enteritis in patients treated with immune checkpoint inhibitor therapy.
Article in Annals of gastroenterology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Authors' reply.Annals of gastroenterologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immune checkpoint inhibitors (ICIs) commonly cause colitis, but isolated immune-mediated enteritis (IMEN) is poorly characterized. This study describes the clinical features, diagnostic findings, and outcomes of IMEN. Method: We retrospectively identified adults with cancer who developed IMEN within one year of ICI initiation, confirmed as duodenitis, ileitis, or both. Results: Among 20,991 ICI-treated patients, 30 (0.143%) developed isolated IMEN. Median age was 69.5 years; 73.3% were male, and 80% white. The most common malignancies were gastrointestinal/hepatobiliary (26.7%) and melanoma (23.3%). Presenting symptoms included nausea (66.7%), diarrhea (53.3%), and vomiting (46.7%); 62.5% of patients with diarrhea had grade ≥2 severity. Disease involved duodenitis plus ileitis in 50%, isolated duodenitis in 30%, and isolated ileitis in 20%. Median fecal calprotectin levels were highest in duodenitis plus ileitis (1335.5 μg/g), followed by ileitis (319 μg/g) and duodenitis (78 μg/g). Endoscopy showed nonulcerative inflammation in 60% and ulceration in 20%. Hospitalization was longest in duodenitis plus ileitis (median 13.5 days). Corticosteroids were required in 66.7% of ileitis cases; additional immunosuppression was needed in 33.3% of ileitis and 66.7% of duodenitis plus ileitis. Isolated duodenitis improved with supportive therapy alone. Remission occurred in 63.3% overall. ICI therapy was resumed in 12.5%, exclusively in patients with isolated duodenitis. Complications included fistula formation (10%); all-cause mortality was 36.7%. Conclusions: IMEN is a rare but clinically significant ICI-related toxicity. Fecal calprotectin correlates with ileitis severity and not duodenitis, and small-bowel endoscopy facilitates diagnosis and management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.